Caris Life Sciences (NASDAQ:CAI) Coverage Initiated at The Goldman Sachs Group

The Goldman Sachs Group began coverage on shares of Caris Life Sciences (NASDAQ:CAI) in a report issued on Wednesday. The brokerage set a “buy” rating and a $27.00 price target on the stock. The Goldman Sachs Group’s price target suggests a potential upside of 51.01% from the company’s current price.

Several other brokerages have also recently issued reports on CAI. Weiss Ratings reissued a “sell (d)” rating on shares of Caris Life Sciences in a research report on Monday, December 29th. Wall Street Zen raised shares of Caris Life Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Robert W. Baird increased their target price on shares of Caris Life Sciences from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Friday, February 27th. BTIG Research decreased their price target on shares of Caris Life Sciences from $45.00 to $38.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Finally, Canaccord Genuity Group dropped their price target on shares of Caris Life Sciences from $30.00 to $22.00 and set a “hold” rating for the company in a research note on Friday, March 13th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $30.60.

Caris Life Sciences Trading Up 6.1%

CAI stock opened at $17.88 on Wednesday. The company has a fifty day moving average price of $20.56. Caris Life Sciences has a 12-month low of $16.28 and a 12-month high of $42.50. The company has a debt-to-equity ratio of 0.66, a current ratio of 7.85 and a quick ratio of 7.35. The stock has a market cap of $5.05 billion and a P/E ratio of -99.33.

Caris Life Sciences (NASDAQ:CAI) last announced its earnings results on Thursday, February 26th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.27. The firm had revenue of $292.89 million for the quarter, compared to analysts’ expectations of $281.00 million. The business’s revenue was up 125.4% compared to the same quarter last year. During the same quarter last year, the business earned ($1.73) earnings per share.

Hedge Funds Weigh In On Caris Life Sciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. Diversified Trust Co. acquired a new stake in Caris Life Sciences in the fourth quarter valued at approximately $540,000. Olistico Wealth LLC acquired a new position in Caris Life Sciences during the 4th quarter worth approximately $31,000. Zevenbergen Capital Investments LLC acquired a new position in Caris Life Sciences during the 4th quarter worth approximately $14,655,000. Hamilton Lane Advisors LLC purchased a new stake in shares of Caris Life Sciences in the 4th quarter valued at approximately $1,584,000. Finally, Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Caris Life Sciences by 26.5% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 75,330 shares of the company’s stock valued at $2,032,000 after purchasing an additional 15,778 shares in the last quarter.

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.